Literature DB >> 20652930

Discovery of 1-(2,4-dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide as a potential peripheral cannabinoid-1 receptor inverse agonist.

Ming-Shiu Hung1, Chun-Ping Chang, Ting-Chieh Li, Teng-Kuang Yeh, Jen-Shin Song, Yinchiu Lin, Chien-Huang Wu, Po-Chu Kuo, Prashanth K Amancha, Ying-Chieh Wong, Wen-Chi Hsiao, Yu-Sheng Chao, Kak-Shan Shia.   

Abstract

Mesh:

Substances:

Year:  2010        PMID: 20652930     DOI: 10.1002/cmdc.201000246

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


× No keyword cloud information.
  5 in total

1.  Exploring structural requirements for peripherally acting 1,5-diaryl pyrazole-containing cannabinoid 1 receptor antagonists for the treatment of obesity.

Authors:  Mayank Kumar Sharma; Prashant R Murumkar; Rajani Giridhar; Mange Ram Yadav
Journal:  Mol Divers       Date:  2015-07-17       Impact factor: 2.943

Review 2.  Re-visiting the Endocannabinoid System and Its Therapeutic Potential in Obesity and Associated Diseases.

Authors:  Joyce M Richey; Orison Woolcott
Journal:  Curr Diab Rep       Date:  2017-09-14       Impact factor: 4.810

3.  Pyrazole antagonists of the CB1 receptor with reduced brain penetration.

Authors:  Alan Fulp; Yanan Zhang; Katherine Bortoff; Herbert Seltzman; Rodney Snyder; Robert Wiethe; George Amato; Rangan Maitra
Journal:  Bioorg Med Chem       Date:  2016-01-18       Impact factor: 3.641

Review 4.  Cannabis: From a Plant That Modulates Feeding Behaviors toward Developing Selective Inhibitors of the Peripheral Endocannabinoid System for the Treatment of Obesity and Metabolic Syndrome.

Authors:  Shira Hirsch; Joseph Tam
Journal:  Toxins (Basel)       Date:  2019-05-15       Impact factor: 4.546

5.  New role of phenothiazine derivatives as peripherally acting CB1 receptor antagonizing anti-obesity agents.

Authors:  Mayank Kumar Sharma; Jatin Machhi; Prashant Murumkar; Mange Ram Yadav
Journal:  Sci Rep       Date:  2018-01-26       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.